528 related articles for article (PubMed ID: 30138325)
1. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
[TBL] [Abstract][Full Text] [Related]
3. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
[TBL] [Abstract][Full Text] [Related]
5. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemoradiotherapy combined with operation vs. operation alone for resectable esophageal cancer: Meta-analysis on randomized controlled trials].
Duan X; Yu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jul; 20(7):809-815. PubMed ID: 28722096
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
Petrelli F; Ghidini M; Barni S; Sgroi G; Passalacqua R; Tomasello G
Gastric Cancer; 2019 Mar; 22(2):245-254. PubMed ID: 30483986
[TBL] [Abstract][Full Text] [Related]
8. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.
Liu B; Bo Y; Wang K; Liu Y; Tang X; Zhao Y; Zhao E; Yuan L
Oncotarget; 2017 Mar; 8(12):20410-20417. PubMed ID: 28099899
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
10. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis.
Zhu Y; Chen J; Sun X; Lou Y; Fang M; Zhou F; Zhang L; Xin Y
Front Oncol; 2023; 13():1177557. PubMed ID: 37228495
[TBL] [Abstract][Full Text] [Related]
11. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
14. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
Radiat Oncol; 2019 Oct; 14(1):176. PubMed ID: 31619265
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis.
Jiang L; Yang KH; Guan QL; Chen Y; Zhao P; Tian JH
J Clin Gastroenterol; 2015; 49(5):387-94. PubMed ID: 25144898
[TBL] [Abstract][Full Text] [Related]
17. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.
Chan KKW; Saluja R; Delos Santos K; Lien K; Shah K; Cramarossa G; Zhu X; Wong RKS
Int J Cancer; 2018 Jul; 143(2):430-437. PubMed ID: 29441562
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
